Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Shares Outstanding (Weighted Average) (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $24.4 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 117.11% year-over-year to $24.4 million; the TTM value through Dec 2025 reached $24.4 million, up 117.11%, while the annual FY2025 figure was $24.4 million, 117.11% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $24.4 million in Q4 2025 for Artiva Biotherapeutics, roughly flat from $24.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $24.4 million in Q4 2025 and bottomed at $800889.0 in Q2 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $10.9 million, with a median of $6.9 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) rose 1.2% in 2024 and then skyrocketed 2906.08% in 2025.
  • Artiva Biotherapeutics' Shares Outstanding (Weighted Average) stood at $802747.0 in 2023, then surged by 1302.54% to $11.3 million in 2024, then skyrocketed by 117.11% to $24.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $24.4 million, $24.4 million, and $24.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.